IFNG and COVID-19: Indeed, a previous study (Leung et al, 2020) have demonstrated that clinical-grade SC2-STs can be obtained from convalescent donors using the IFN-γ capture technology, with a sufficient cell count to be used as T cell therapy in COVID-19 hospitalized patients.